Research shows that PD-1/PD-L1 inhibitors exert anti-tumor effects by rescuing exhausted CD8+ T cells in GIST through the blockade of the PI3K/AKT/mTOR signaling pathway [15]. This evidence concerns the gene CD274 and neoplasm.